Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Scand J Rheumatol ; 39(3): 229-32, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20109079

RESUMEN

OBJECTIVES: To determine the pathological features of sacroiliitis and the expression of cytokines in joint biopsy samples in patients with ankylosing spondylitis (AS) and to investigate the variance in single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) scans, and the response to intra-articular injection of anti-tumour necrosis factor (TNF) therapy. METHODS: Sixteen patients with AS were given CT-guided intra-articular injections of etanercept at 0, 4, and 8 weeks (25 mg per dose). Pathological features of sacroiliitis were observed with light microscopy and immunohistochemistry. Expression of cytokines in joint biopsy samples was estimated by reverse transcription polymerase chain reaction (RT-PCR). Imageological changes in sacroiliitis were observed by SPECT/CT and MRI. All patients were followed up clinically. RESULTS: In all 16 patients who received intra-articular etanercept, sacroiliac joint (SIJ) region of interest (ROI) mean values determined by SPECT improved significantly after 8 weeks (p < 0.05). Bone marrow hydropsia and fatty deposition detected on MRI were relieved significantly after 8 weeks (p < 0.05). In eight patients the expression of TNFalpha and transforming growth factor (TGF)-beta mRNA in joint tissue decreased significantly after 8 weeks (p < 0.05). The frequency of synovitis, enthesitis, chondritis, subchondral bony plate destruction, and bone marrow inflammation decreased significantly, along with the inflammatory cell index (p < 0.05). Participants showed significant clinical improvement after 8 and 12 weeks (p < 0.001) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score but no significant difference in spondylitis and periphery arthritis (p > 0.05). This mode of treatment had no notable adverse events. CONCLUSIONS: This study has shown that intra-articular injection of etanercept in SIJ can improve joint function. It has a satisfactory safety profile and is cost-effective. This mode of treatment is most beneficial in local arthropathy of recent onset.


Asunto(s)
Inmunoglobulina G/administración & dosificación , Inyecciones Intraarticulares/métodos , Receptores del Factor de Necrosis Tumoral/administración & dosificación , Articulación Sacroiliaca/efectos de los fármacos , Espondilitis Anquilosante/tratamiento farmacológico , Análisis de Varianza , Antirreumáticos/administración & dosificación , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/metabolismo , Esquema de Medicación , Etanercept , Humanos , Inmunohistoquímica , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/patología , Interleucina-6/metabolismo , Imagen por Resonancia Magnética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Articulación Sacroiliaca/metabolismo , Articulación Sacroiliaca/patología , Índice de Severidad de la Enfermedad , Espondilitis Anquilosante/metabolismo , Espondilitis Anquilosante/patología , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA